O-Aryl-Glycoside Ice Recrystallization Inhibitors as Novel Cryoprotectants: A Structure–Function Study

Chantelle J. Capicciotti,† Ross S. Mancini,† Tracey R. Turner,‡ Toshie Koyama,§ Matthew G. Alteen,† Malay Doshi,† Takaaki Inada,§ Jason P. Acker,† and Robert N. Ben†,‡

†Department of Chemistry, University of Ottawa, D’Iorio Hall, 10 Marie Curie, Ottawa, Ontario K1N 6NS, Canada
‡Canadian Blood Services, Centre for Innovation, 8249-114 Street NW, Edmonton, Alberta T6G 2R8, Canada
§National Institute of Advanced Industrial Science and Technology (AIST), 1-2-1 Namiki, Tsukuba, Ibaraki 305-8564, Japan

ABSTRACT: Low-molecular-weight ice recrystallization inhibitors (IRIs) are ideal cryoprotectants that control the growth of ice and mitigate cell damage during freezing. Herein, we describe a detailed study correlating the ice recrystallization inhibition activity and the cryopreservation ability with the structure of O-aryl-glycosides. Many effective IRIs are efficient cryoadditives for the freezing of red blood cells (RBCs). One effective cryoadditive did not inhibit ice recrystallization but instead inhibited ice nucleation, demonstrating the significance of inhibiting both processes and illustrating the importance of this emerging class of cryoprotectants.

INTRODUCTION

The development of highly efficient methods to cryopreserve cells, tissues, and organs is becoming exceedingly important to meet the increasing demands of emerging cellular therapies. Cryopreservation of blood and stem cells has had tremendous impact on regenerative and transfusion medicine. Hematopoietic stem cells from umbilical cord blood are used in therapies to treat immunodeficiencies and hematological cancers.1,2 Red blood cells (RBCs) are also in high demand for lifesaving transfusions and in the treatments of hematological cancers and anemias. Currently, RBC storage is limited to 42 days at 4 °C, which can result in blood shortages when high numbers of emergency transfusions are required.3 Although cryopreservation can extend the storage time to 10 years, major limitations to current protocols largely limit this preservation method to rare blood types and autologous RBCs.3−5

Dimethyl sulfoxide (DMSO) and glycerol are the most commonly used cryoprotectants, and both readily penetrate cell membranes.6−8 Although these are efficient and result in high post-thaw cell viability, issues arise from toxicity both on a cellular level and in a clinical setting when directly transfused into patients.9−11 For RBCs, the cryoprotectant must be removed after thawing before transfusion, which is a costly and time-consuming process that precludes the routine use of frozen RBC units. In North America, RBCs are cryopreserved in 40% glycerol using a slow freezing rate (approx. 1 °C/min), and glycerol must be reduced to less than 1% before transfusion to avoid intravascular hemolysis, a process that can take up to 1 h.4,12 New cryoprotectants that can eliminate or reduce the amount of glycerol (and DMSO) will greatly improve the logistical issues associated with managing inventories of frozen cells and tissues, making these more accessible for lifesaving therapies.

Ice recrystallization is a significant contributor to cellular damage and death during the freezing and thawing steps of the cryopreservation process.13−15 Thus, there is tremendous interest in designing compounds that are effective ice recrystallization inhibitors (IRIs) to mitigate this damage and improve cellular viability and function post-thaw.16−20 Anti-freeze (glyco)proteins [AF(G)Ps] are nature’s most potent IRIs;1−2 however, they often fail as cryoprotectants because of their ability to bind to ice and alter the ice crystal habit, which is detrimental to cells.24−27 Large peptides and glycopeptide analogues of AF(G)Ps28−30 and high-molecular-weight polymers31−33 such as poly(vinyl alcohol) (PVA) have also been explored as cryoprotectants. However, small molecules with molecular masses less than 300 atomic mass units are highly attractive alternatives that can be efficiently synthesized and are amenable to large-scale preparations. Furthermore, there is less likelihood of nonspecific toxic effects and immunogenic responses that can be associated with peptides or proteins.

Prior work by our group has demonstrated that small amphiphilic carbohydrate-based and amino acid-based molecules can be very effective IRIs.34−36 Recently, our group has reported two novel glucose-based O-aryl-glycosides, β-PMP-
positive control. The error bars indicate standard error of the mean less hydrated glucose head groups.29,34,38 To further explore hydrated galactose head group were better IRIs than those with described that pyranose-based derivatives containing a more surprising because previous reports from our laboratory addition, a direct connection of the aryl ring to the C1 oxygen is highly active, whereas the methyl group of the −OMe is crucial for the activity of β-PMP-Glc because replacement of this moiety with an −OH or −OCF3 (4 and 15) group decreased activity. An oxygen atom connecting the aryl ring and the methyl group is also important because 5 resulted in a similar reduction in activity.

The O-aryl-galactosides exhibit a very different activity profile than the glucoses. Most galactosides had weak activity that was much less than that of galactose (Figure 1B). Potent activity was observed with −Cl and −Br substituents (21–22); however, the fluoro-derivative 20 was inactive. In general, the galactosides were less active than the corresponding glucose derivatives. Exceptions include 16, 24, and 26 with a para−NH2, −CO2Me, or −NO2 group, compared with analogous electronic derivatives 3, 11, and 13. Overall, it is evident that electronic effects do not influence the ice recrystallization inhibition ability of the O-aryl-glycosides in any obvious manner. In the glucoside series, −OMe, −OH, and −NH2 groups (1, 3–4) are all electron-donating groups (EDGs), yet 1 is highly active, whereas 3 is the least active glucose derivative. Moreover, both −NO2 and −CF3 groups are strong electron-withdrawing groups (EWGs); however, the −CF3 derivative 12 was highly active, whereas the −NO2 derivative 13 was only moderately active. In the galactoside series, none of the derivatives with EDGs were active (2, 16–19). The activity of derivatives with EWGs varied from weak (20 and 23) to moderate (25–26) with only 24 exhibiting high activity.

Thus far, in this class of compounds, one of the best IRIs is β-PMP-Glc (1), and it appears that substitution at the para-position with anything other than a methoxy or a halogen group is detrimental for activity. We next sought to explore other derivatives of the β-PMP-Glc structure to determine other structural features that are important for this potent activity (Figure 2). This included exploring the C1 glycosidic bond stereochemistry (29–34), the effect of methoxy group regiochemistry (35–36), and the importance of an O-linkage (37–39) at C1. Unfortunately, all of these modifications were detrimental to IRI activity. An α-linkage greatly reduced the activity (30), a trend that was observed also with the α-linked halogen derivatives 33–34, highlighting the importance of a β-linkage. Similarly, a methoxy group in the para-position was essential as meta- and ortho-derivatives 35–36 displayed moderate activity. It is evident that modifying the O-glycosidic linkage is also detrimental because N- and S-linked PMP derivatives 37–38 had drastically decreased the activity. In addition, a direct connection of the aryl ring to the C1 oxygen is crucial because the para-methoxybenzyl derivative 39 was also inactive. Finally, conjugating the O-PMP group to the C6 position (40) rather than C1 also resulted in weak activity.

Figure 1. Structures and IRI activity of β-linked para-substituted (A) β-PMP-Glc (1) and O-aryl-glucosides 3–15 and (B) β-PMP-Gal (2) and O-aryl-galactosides 16–28. All compounds were assessed at 22 mM in PBS. IRI activity is represented as % MGS relative to the PBS positive control. The error bars indicate standard error of the mean (SEM).
The IRI activity of β-PMP-Glc is highly sensitive to the relative orientation of the hydroxyl groups on the pyranose ring. Equatorial C2 and C4 hydroxyl groups are required because β-PMP-Gal (2) and β-PMP-Man (29) were weakly active (Figure 2). Furthermore, the C6-hydroxymethyl group is also important because removing this group (xylose derivative 41), methylating this position (42), and extending this position by one carbon (43) diminished activity (Figure 3). Glycosylating the C6 position of β-PMP-Glc resulted in a similar decrease in activity, and this was independent of the glycosidic-bond stereochemistry or whether the conjugated para-substituent was another glucose residue. The C6-phenyl group in which the para-substituent was a galactose unit (β-PMP-Man (29)) diminished activity (Figure 3). Interestingly, glycosylation at the C2 position appears to be tolerated with little change in activity. β-PMP-lactose 47 had better activity than disaccharides 44–46, although its activity was diminished compared with that of the parent β-PMP-Glc. Collectively, these results highlight the importance of the various hydroxyl groups on the pyranose ring of β-PMP-Glc and how the C6-OH is particularly sensitive to modifications.

Other disaccharides assessed for activity were the dihydroxybenzene-linked disaccharides 48–50. These were 1,1-linked using an O-phenyl group in which the para-substituent was a second β-linked galactose or glucose residue (Figure 3). Interestingly, disaccharide 48 containing two β-linked glucose units had potent IRI activity that was slightly less than that of β-PMP-Glc. Thus, it appears that replacing the para-methoxy substituent with another glucose residue retains activity. Conversely, when the para-substituent was a galactose unit (49), only moderate IRI activity was observed. Disaccharide 50 containing two galactose units had weak activity that was similar to that of the monosaccharide β-PMP-Gal (2), indicating that the additional galactose unit had no effect on ice recrystallization inhibition.

Overall, the ice recrystallization inhibition data of the O-aryl-glycosides uncovered a few compounds in this class of molecules that are highly efficient IIRIs. Having previously reported that both β-PMP-Glc (1) and β-pBrPh-Glc (9) are also effective cryoadditives for RBCs,37 we investigated the cryoprotective ability of many of these derivatives. This would provide insight into the structural features of β-PMP-Glc that are beneficial for its cryoprotective ability and would also allow us to explore the relationship between ice recrystallization inhibition and the cryopreservation ability for this class of compounds. Two freezing protocols were used to cryopreserve human RBCs in cryoprotective solutions containing a reduced quantity of glycerol (15%) with or without the O-aryl-glycoside additives. A two-step slow-freezing protocol was used where samples were cooled at a rate of 1 °C/min to −40 °C, then immediately stored at −80 °C before thawing.8,41 This is representative of the current clinical RBC cryopreservation protocols used in North America with high glycerol concentrations (40%).3,12,42,43 A rapid-freezing protocol was also used where samples were dumped into dry ice (−80 °C) to achieve rapid freezing rates.3,4,44 O-Aryl-glycoside derivatives were assessed at concentrations previously determined to be most effective for β-PMP-Glc (1) and β-pBrPh-Glc (9).37 Post-thaw hemolysis was quantified using the Drabkin’s assay.45,46 RBC freezing results (Figure 4) are reported as a percentage of post-thaw integrity (100 − % hemolysis). O-Aryl-glycosides that have a potent IRI activity are indicated by a diamond (●) to easily identify the RBC freezing results of these compounds.

With the slow-freezing protocol, 110 mM β-PMP-Glc in 15% glycerol doubles the post-thaw RBC integrity (50%) of the 15% glycerol control (25%). Other derivatives with potent IRI activity, such as β-pFPh-Glc (7) and β-pBrPh-Glc (9),
furnished similar results. It is interesting to note that 9 is more effective at 30 mM than at 55 mM, suggesting that toxicity may be an issue with this particular compound. Disaccharides 48, which was a moderate inhibitor of ice recrystallization, failed to increase post-thaw integrity and was worse than 15% glycerol. Many of the less-active glucosides failed to give post-thaw integrity higher than the glycerol control (25%–30%, 4, 6, 15). Surprisingly, β-pMePh-Glc (5) and α-PMP-Glc (30) had similar post-thaw integrities as β-PMP-Glc (50%–60%) despite being less active. It appears that simply the presence of the methyl group either directly connected to the aryl ring (5) or linked through an oxygen atom (1) is sufficient for RBC freezing, and removal of this group (with 4 and 6) abolishes any cryoprotective effect. In contrast to ice recrystallization inhibition, cryoprotective ability is not sensitive to C1 glycosidic-bond stereochemistry because α- and β-PMP-Glc had similar post-thaw RBC integrity. When O-aryl-galactosides were used as cryoadditives, β-PMP-Gal (2) in 15% glycerol resulted in a slightly better post-thaw integrity than β-PMP-Glc (65%), despite the fact that this compound was not IRI active. In contrast to the PMP-Glc derivatives, the cryoprotective ability of the Gal derivatives is sensitive to the stereochemistry of the glycosidic-bond because α-PMP-Gal (31) resulted in a low post-thaw integrity similar to 15% glycerol. The fact that 2 and 9 were effective cryoprotectants, yet 2 was not IRI active, was a very surprising and unexpected result. Subsequent experiments have verified that although 2 does not exhibit ice recrystallization inhibition it is a very effective inhibitor of ice nucleation. 47 β-PMP-Gal (2) results in a significantly higher percentage of unfrozen droplets of water when supercooled to −37 °C (Figure 5), inactivating the ice-nucleating agent AgI. This result could explain the ability of 2 to increase the number of post-thaw RBCs because when nucleation is inhibited, a greater degree of supercooling is permitted. The end result of this is that more intracellular water will exit the RBCs, leading to less intracellular ice and less cellular damage.

The highest post-thaw RBC integrity observed with the slow-freezing conditions was with the two compounds that were the most potent ice recrystallization inhibitors, β-pBrPh-Glc (9) and β-pBrPh-Gal (22). The post-thaw integrity was 65% with 55 mM β-pBrPh-Gal (22) and 67% with 30 mM β-pBrPh-Glc (9). Both of these derivatives were also very effective with rapid freezing rates (Figure 4B). The addition of 30 mM of either of these derivatives to 15% glycerol resulted in almost 95% post-thaw integrity, which is significantly higher than that of 15% glycerol (75% integrity). When the glycerol concentration was decreased to 10%, 30 mM β-pBrPh-Glc (9) was still highly effective in preventing post-thaw hemolysis, resulting in almost triple the RBC integrity (67%) compared to that of 10% glycerol (23%).

**CONCLUSIONS**

Overall, the RBC freezing experiments demonstrate that IRIs β-PMP-Glc (1), β-pBrPh-Glc (9), and β-pBrPh-Gal (22) can be used at low concentrations in combination with 15% glycerol to provide high post-thaw RBC integrity with slow freezing rates that are used clinically to cryopreserve RBCs. Currently, this

---

**Figure 4.** Post-thaw RBC integrity after freezing using O-aryl-glycoside IRIs in 15% glycerol cryosolutions. (A) Rate-controlled slow-freezing at 1 °C/min to −40 °C followed by −80 °C storage. (B) Rapid-freezing to −80 °C by plunging into solid CO2 (dry ice). All samples were thawed at 37 °C, and post-thaw RBC hemolysis was determined using the Drabkin’s assay. Results are presented as mean post-thaw % RBC integrity (100 − % hemolysis). The error bars represent SEM. ● indicates compounds with a potent IRI activity.

**Figure 5.** Fraction f of unfrozen droplets for water and different aqueous solutions 1, 2, and 9 at 22 mM with AgI particles (5 < d ≤ 25 μm, 2 ≤ NAgI ≤ 8) as a function of the sample temperature.
After the annealing time, a digital camera (Nikon CoolPix) was used to analyze each image and employed a Microsoft Windows Graphical Interface to allow for the demarcation and storage of the vertices of ice domains in a digital micrograph. For each wafer, three images were obtained from whole blood units by centrifugation at 4 °C (Hct) of 0.50 L/L. Leukoreduced RBCs were stored refrigerated (4–6 °C) in the buffer solution for up to 1 week.

**RBC Freezing Experiments.** Freezing solutions containing carbohydrate compounds were prepared at twice the desired final concentration in the 0.2%/0.9% dextrose/saline buffer. The freezing solution (150 μL) was added to 150 μL of leukoreduced RBCs for a final volume of 300 μL. The final concentrations of all freezing solutions are indicated in the text. After transfer to cryotubes, the RBC suspensions were incubated for 10 min at room temperature, then immersed in a methanol bath cooled to −5 °C. A glycerol sample with a thermostore was used as a control to measure the temperature of the solution in 1 s intervals. Once the internal solution reached −5 °C, ice nucleation was induced with forceps precooled in liquid nitrogen and the samples were held at −5 °C for 5 min. Slow freezing conditions were achieved by cooling at a rate of 1 °C/min to −40 °C in a methanol bath, followed by plunging the samples into dry ice (−80 °C) and storing in a −80 °C mechanical freezer. Rapid freezing conditions were achieved by plunging into dry ice (−80 °C) and storing for a minimum of 30 min.

**Thawing and Post-Thaw Hemolysis.** Fast-thaw conditions in a 37 °C water bath were used for all samples. Hcts and percentage hemolysis were assessed immediately post-thaw for all samples. The percentage post-thaw hemolysis (%) was determined using the cyanmethemoglobin Drabkin’s method by comparing the supernatant hemoglobin concentration to total hemoglobin concentration. The percentage post-thaw RBC integrity was calculated using the following equation: % post-thaw RBC integrity = 100% − % hemolysis. Data for a minimum of four replicates for each condition are represented as the mean post-thaw RBC integrity.

**Ice Nucleation Inhibition Assay.** Compounds were assessed for ice nucleation inhibition using the ice-nucleating agent silver iodide (AgI) as previously described. Briefly, water-in-oil (W/O) emulsions containing AgI particles were prepared by suspending 0.2 g of AgI in 4 mL of purified deionized (DI) water in a glass vial. The suspension was sonicated for 60 min at room temperature and then immediately filtered through a filter paper to remove large AgI particles and aggregates, leaving only AgI particles of ≤3 μm in diameter in the suspension. The aqueous solutions of each compound (except β-pBrPh-Glc) were prepared at three times the desired final concentration, and 1 mL of these aqueous solutions or water (control) was mixed with 2 mL of the AgI suspension. The aqueous solutions of 22 mM β-pBrPh-Glc were prepared at twice the desired final concentration because of the solubility limitation, and 1.5 mL of this aqueous solution was mixed with the same volume of the AgI suspension. The 3 mL mixtures were emulsified in 6 mL of n-heptane containing 4 wt % SPAN 65 in a glass vial. The ice nucleation temperature T was determined for each droplet of the W/O emulsion by observing the freezing of the droplets by using optical microscopy. Before cooling, the droplet diameter d was measured and the number of AgI particles (N AgI) inside of the droplet was counted. In this study, the data that satisfied S < d < 2S μm and 2 ≤ N AgI ≤ 8 were adopted.

**METHODS**

All methods were carried out in accordance with approved guidelines.

**Preparation of O-Aryl-Glycosides.** Experimental procedures and spectroscopic data for the preparation of O-aryl-glycosides are described in the Supporting Information.

**Ice Recrystallization Inhibition Activity.** Ice recrystallization inhibition activity was measured using a “splat cooling” assay. All compounds were assessed in a PBS solution. The sample solution (10 μL) was dropped from a micropipette onto a polished aluminum block precooled to −6.4 °C to anneal for 30 min. After the annealing time, a digital camera (Nikon CoolPix 5000) fitted to a microscope was used to photograph the ice crystals present in the wafer. For each wafer, three images were used to quantify the area of 12 ice crystals within the image (n = 36 crystals per drop), and three drops of each sample were assayed (n = 108 per sample). A domain recognition software (DRS) program was used to analyze each image and employed a Microsoft Windows Graphical Interface to allow for the demarcation and storage of the vertices of ice domains in a digital micrograph to calculate the domain areas of each crystal. All data were plotted and analyzed using Microsoft Excel to provide the MGS of the sample and a PBS control on the same day of testing. The MGS of the sample was compared to that of the PBS control to obtain the ice recrystallization inhibition activity, reported as the percentage of the MGS (% MGS) relative to the PBS control. A large % MGS represents larger ice crystals, which is indicative of low IRI activity.

**Blood Collection and Preparation.** Canadian Blood Services Network Centre for Applied Development (NetCAD) provided all whole blood units, which were obtained in accordance with the standardized phlebotomy guidelines approved by Canadian Blood Services (CBS). Experimental protocols were approved by CBS and NetCAD, and ethics approvals were obtained from the Research Ethics Board (REB) at CBS and the University of Alberta. RBCs were obtained from whole blood units by centrifugation at 4 °C and 2200g for 10 min, followed by removal of the plasma supernatant and the buffy coat from the RBC pellet. Pelleted RBCs were washed twice with the 0.2%/0.9% dextrose/saline buffer, then resuspended in an equal volume of packed RBCs in the 0.2%/0.9% dextrose/saline buffer to a final hematocrit (Hct) of 0.50 L/L. Leukoreduced RBCs were stored refrigerated (4–6 °C) in the buffer solution for up to 1 week.

**ASSOCIATED CONTENT**

**Supporting Information**

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acsomega.6b00163.
Experimental procedures and spectroscopic data for new compounds (PDF)

Author Information
Corresponding Author
*E-mail: rben@uottawa.ca. Phone: 1-613-562-5800.
Notes
The authors declare no competing financial interest.

Acknowledgments
The authors gratefully acknowledge the Natural Sciences and Engineering Research Council of Canada (NSERC), Canadian Blood Services (CBS), and the Canadian Institutes of Health Research (CIHR) for financial support. C.J.C. thanks CBS for a Graduate Fellowship Program (GFP) award.

References
(1) Hunt, C. J. Cryopreservation of human stem cells for clinical application: A review. Transfus. Med. Hemother. 2011, 38, 107–123.
(2) Harris, D. T. Non-haematological uses of cord blood stem cells. Br. J. Haematol. 2009, 147, 177–184.
(3) Scott, K. L.; Lecak, J.; Acker, J. P. Biopreservation of red blood cells: Past, present, and future. Transfus. Med. Rev. 2005, 19, 127–142.
(4) Hess, J. R. Red cell freezing and its impact on the supply chain. Transfus. Med. 2004, 14, 1–8.
(5) Hess, J. R.; Greenwalt, T. G. Storage of red blood cells: New approaches. Transfus. Med. Rev. 2002, 16, 283–295.
(6) Meryman, H. T. Cryopreservation of living cells: Principles and practice. Transfusion 2007, 47, 935–945.
(7) Meryman, H. T. Cryoprotective agents. Cryobiology 1971, 8, 173–183.
(8) McGann, L. E. Differing actions of penetrating and non-penetrating cryoprotective agents. Cryobiology 1978, 15, 382–390.
(9) Fahy, G. M. The relevance of cryoprotectant “toxicity” to cryobiology. Cryobiology 1986, 23, 1–13.
(10) Davis, J. M.; Rowley, S. D.; Braine, H. G.; Plantadosi, S.; Santos, G. W. Clinical toxicity of cryopreserved bone marrow graft infusion. Blood 1990, 75, 781–786.
(11) Zambelli, A.; Poggi, G.; Da Prada, G. A.; Pedrazzoli, P.; Cuomo, A.; Miotti, D.; Perotti, C.; Preti, P.; Robustelli Della Cuna, G. Clinical toxicity of cryopreserved circulating progenitor cells infusion. Anticancer Res. 1998, 18, 4705–4708.
(12) Meryman, H. T.; Hornblower, M. A method for freezing and washing red blood cells using a high glycerol concentration. Transfusion 1972, 12, 145–156.
(13) Mazur, P. Cryobiology: The freezing of biological systems. Science 1970, 168, 939–949.
(14) Mazur, P. Freezing of living cells: Mechanisms and implications. Am. J. Physiol. 1984, 247, C125–C142.
(15) Fowler, A.; Toner, M. Cryo-injury and biopreservation. Ann. N. Y. Acad. Sci. 2005, 1066, 119–135.
(16) Garner, J.; Harding, M. M. Design and synthesis of antifreeze glycoproteins and mimics. ChemBioChem 2010, 11, 2489–2498.
(17) Peltier, R.; Brimble, M. A.; Wojnar, J. M.; Williams, D. E.; Evans, C. W.; DeVries, A. L. Synthesis and antifreeze activity of fish antifreeze glycoproteins and their analogues. Chem. Sci. 2010, 1, 538–551.
(18) Gibson, M. I. Slowing the growth of ice with synthetic macromolecules: Beyond antifreeze (glyco) proteins. Polym. Chem. 2010, 1, 1141–1152.
(19) Balcerzak, A. K.; Capicciotti, C. J.; Biard, J. G.; Ben, R. N. Designing ice recrystallization inhibitors: From antifreeze (glyco)-proteins to small molecules. RSC Adv. 2014, 4, 42682–42696.
(20) Capicciotti, C. J.; Doshi, M.; Ben, R. N. Ice recrystallization inhibitors: From biological antifreezes to small molecules. In Recent Developments in the Study of Recrystallization; Wilson, P., Ed.; InTech: New York, 2013; pp 177–224.
(21) Feeney, R. E.; Burcham, T. S.; Yeh, Y. Antifreeze glycoproteins from polar fish blood. Annu. Rev. Biophys. Biophys. Chem. 1986, 15, 59–78.
(22) Yeh, Y.; Feeney, R. E. Antifreeze proteins: Structures and mechanisms of function. Chem. Rev. 1996, 96, 601–618.
(23) Harding, M. M.; Anderberg, P. I.; Haymet, A. D. J. ‘Antifreeze’ glycoproteins from polar fish. Eur. J. Biochem. 2003, 270, 1381–1392.
(24) Wang, J.-H. A comprehensive evaluation of the effects and mechanisms of antifreeze proteins during low-temperature preservation. Cryobiology 2000, 41, 1–9.
(25) Carpenter, J. F.; Hansen, T. N. Antifreeze protein modulates cell survival during cryopreservation: Mediation through influence on ice crystal growth. Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 8953–8957.
(26) Chao, H.; Davies, P. L.; Carpenter, J. F. Effects of antifreeze proteins on red blood cell survival during cryopreservation. J. Exp. Biol. 1996, 199, 2071–2076.
(27) Capicciotti, C. J.; Poisson, J. S.; Boddy, C. N.; Ben, R. N. Modulation of antifreeze activity and the effect upon post-thaw HepG2 cell viability after cryopreservation. Cryobiology 2015, 70, 79–89.
(28) Liu, S.; Ben, R. N. C-linked galactosyl serine AFGP analogues as potent recrystallization inhibitors. Org. Lett. 2005, 7, 2385–2388.
(29) Czechura, P.; Tam, R. Y.; Dimitrijevic, E.; Murphy, A. V.; Ben, R. N. The importance of hydration for inhibiting ice recrystallization with C-linked antifreeze glycoproteins. J. Am. Chem. Soc. 2008, 130, 2928–2929.
(30) Leclère, M.; Kwok, B. K.; Wu, L. K.; Allan, D. S.; Ben, R. N. C-linked antifreeze glycoprotein (C-AFGP) analogues as novel cryoprotectants. Bioconjugate Chem. 2011, 22, 1804–1810.
(31) Gibson, M. I.; Barker, C. A.; Spain, S. G.; Albertin, L.; Cameron, N. R. Inhibition of ice crystal growth by synthetic glycopolymers: Implications for the rational design of antifreeze glycoprotein mimics. Biomacromolecules 2009, 10, 326–333.
(32) Inada, T.; Lu, S.-S. Thermal hysteresis caused by nonequilibrium antifreeze activity of poly(vinyl alcohol). Chem. Phys. Lett. 2004, 394, 361–365.
(33) Budke, C.; Koop, T. Ice recrystallization inhibition and molecular recognition of ice faces by poly(vinyl alcohol). Chem. PhysChem 2006, 7, 2601–2606.
(34) Capicciotti, C. J.; Leclère, M.; Perras, F. A.; Bryce, D. L.; Paulin, H.; Harden, J.; Liu, Y.; Ben, R. N. Potent inhibition of ice recrystallization by low molecular weight carbohydrate-based surfactants and hydrogelsators. Chem. Sci. 2012, 3, 1408–1416.
(35) Tran, J. F.; Biggs, R. A.; Capicciotti, C. J.; Ben, R. N. Developing highly active small molecule ice recrystallization inhibitors based upon C-linked antifreeze glycoprotein analogues. RSC Adv. 2013, 3, 26005–26009.
(36) Balcerzak, A. K.; Febrarobo, M.; Ben, R. N. The importance of hydrophobic moieties in ice recrystallization inhibitors. RSC Adv. 2013, 3, 3232–3236.
(37) Capicciotti, C. J.; Kurach, J. D. R.; Turner, T. R.; Mancini, R. S.; Acker, J. P.; Ben, R. N. Small molecule ice recrystallization inhibitors enable freezing of human red blood cells with reduced glycerol concentrations. Sci. Rep. 2015, 5, 9692.
(38) Tam, R. Y.; Ferreira, S. S.; Czechura, P.; Chaytor, J. L.; Ben, R. N. Hydration index—a better parameter for explaining small molecule hydration in inhibition of ice recrystallization. J. Am. Chem. Soc. 2008, 130, 17494–17501.
(39) Knight, C. A.; Hallett, J.; DeVries, A. L. Solute effects on ice recrystallization: An assessment technique. Cryobiology 1988, 25, 55–60.
(40) Jackman, J.; Noestheden, M.; Moffat, D.; Pezacki, J. P.; Findlay, S.; Ben, R. N. Assessing antifreeze activity of AFGP 8 using domain recognition software. Biochem. Biophys. Res. Commun. 2007, 354, 340–344.
(41) Farrant, J.; Walter, C. A.; Lee, H.; McGann, L. E. Use of two-step cooling procedures to examine factors influencing cell survival following freezing and thawing. Cryobiology 1977, 14, 273–286.
(42) Högman, C. F. Preparation and preservation of red cells. Vox Sang. 1998, 74, 177–187.
(43) Meryman, H. T. Frozen red cells. Transfus. Med. Rev. 1989, 3, 121–127.
(44) Rowe, A. W.; Eyster, E.; Kellner, A. Liquid nitrogen preservation of red blood cells for transfusion: A low glycerol—rapid freeze procedure. Cryobiology 1968, 5, 119–128.
(45) Drabkin, D. L. The standardization of hemoglobin measurement. Am. J. Med. Sci. 1948, 215, 110.
(46) Sowemimo-Coker, S. O. Red blood cell hemolysis during processing. Transfus. Med. Rev. 2002, 16, 46–60.
(47) Koyama, T.; Inada, T.; Kuwabara, C.; Arakawa, K.; Fujikawa, S. Anti-ice nucleating activity of polyphenol compounds against silver iodide. Cryobiology 2014, 69, 223–228.
(48) Inada, T.; Koyama, T.; Goto, F.; Seto, T. Ice nucleation in emulsified aqueous solutions of antifreeze protein type III and poly(vinyl alcohol). J. Phys. Chem. B 2011, 115, 7914–7922.
(49) Inada, T.; Koyama, T.; Goto, F.; Seto, T. Inactivation of ice nucleating activity of silver iodide by antifreeze proteins and synthetic polymers. J. Phys. Chem. B 2012, 116, 5364–5371.